205 related articles for article (PubMed ID: 23685570)
1. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
[TBL] [Abstract][Full Text] [Related]
2. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
Cilibrizzi A; Quinn MT; Kirpotina LN; Schepetkin IA; Holderness J; Ye RD; Rabiet MJ; Biancalani C; Cesari N; Graziano A; Vergelli C; Pieretti S; Dal Piaz V; Giovannoni MP
J Med Chem; 2009 Aug; 52(16):5044-57. PubMed ID: 19639995
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.
Cilibrizzi A; Schepetkin IA; Bartolucci G; Crocetti L; Dal Piaz V; Giovannoni MP; Graziano A; Kirpotina LN; Quinn MT; Vergelli C
Bioorg Med Chem; 2012 Jun; 20(12):3781-92. PubMed ID: 22607879
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
5. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
6. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
7. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
8. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
9. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Khlebnikov AI; Ye RD; Quinn MT
Bioorg Med Chem; 2016 Jun; 24(11):2530-2543. PubMed ID: 27134116
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
Vergelli C; Khlebnikov AI; Crocetti L; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Cilibrizzi A; Quinn MT; Rossi P; Paoli P; Giovannoni MP
Chem Biol Drug Des; 2021 Oct; 98(4):582-603. PubMed ID: 34148303
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.
Khlebnikov AI; Schepetkin IA; Kirpotina LN; Brive L; Dahlgren C; Jutila MA; Quinn MT
J Mol Model; 2012 Jun; 18(6):2831-43. PubMed ID: 22127612
[TBL] [Abstract][Full Text] [Related]
14. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
15. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
16. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
Lind S; Dahlgren C; Holmdahl R; Olofsson P; Forsman H
J Leukoc Biol; 2021 Jun; 109(6):1105-1120. PubMed ID: 33040403
[TBL] [Abstract][Full Text] [Related]
17. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
[TBL] [Abstract][Full Text] [Related]
18. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT
Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845
[TBL] [Abstract][Full Text] [Related]
19. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.
Khlebnikov AI; Schepetkin IA; Quinn MT
Eur J Med Chem; 2010 Nov; 45(11):5406-19. PubMed ID: 20870313
[TBL] [Abstract][Full Text] [Related]
20. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A
Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
